Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized ...

Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme (TEM-GBM) study, with 25 patients ...

When the macrophages’ ability to consume dying cancer cells or Upd3 production was decreased, tumor growth was significantly reduced.

Richard Staines spoke with Soren Bregenholt, the new CEO of Macrophage Pharma, about the company’s strategy encompassing both immune oncology and inflammatory diseases. In healthy tissues ...

Unravel Complex Macrophage Biology, Accelerate Novel Target Discovery, & Drive Clinical Proof of Concept to Deliver the Blockbuster Potential of Macrophage Therapeutics in Oncology & Beyond ...

Interactive Chart for Tempus AI, Inc. (TEM), analyze all the data with a huge range of indicators.